Skip to content
OCUT-2C
Tissue
胸膜
Disease
甲状腺无细胞癌
Metastatic site
胸腔积液
Synonyms
Ocut-2C, OCUT2C, Osaka City University Thyroid-2C

Documents

OCUT-2C

Cell line · Product number 305544

OCUT-2C (Osaka City University Thyroid-2C) is a human anaplastic thyroid carcinoma cell line established from a pleural effusion of an 81-year-old Japanes...

US$700.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

OCUT-2C(大阪市立大学甲状腺-2C)是一种从一名81岁日本女性患者的胸腔积液中建立的人类未分化甲状腺癌细胞系。该细胞系以粘附性单层形式生长。OCUT-2C携带两种具有临床意义的致癌突变: BRAF p.Val600Glu (V600E) 和 PIK3CA p.His1047Arg (H1047R),这反映了去分化型和未分化型甲状腺癌中常见的 MAPK 和 PI3K/Akt 通路同时激活现象。 BRAF V600E 和 PIK3CA H1047R 的同时存在,为研究未分化甲状腺癌的耐药机制及联合治疗策略提供了一个具有临床相关性的模型。

OCUT-2C 适用于研究未分化甲状腺癌的生物学特性、BRAF V600E + PI3K H1047R 共突变的生物学机制、MAPK/ERK 和 PI3K/Akt 信号传导通路、靶向治疗评估(BRAF 抑制剂、MEK 抑制剂、 PI3K/mTOR 抑制剂)以及联合治疗方案。作为源自日本患者的未分化甲状腺癌模型,它对于研究这种预后极差、具有侵袭性和耐药性特征的恶性肿瘤的生物学特性具有重要意义。

Tissue
胸膜
Disease
甲状腺无细胞癌
Metastatic site
胸腔积液
Applications
甲状腺未分化癌研究;BRAF V600E 与 PIK3CA H1047R 共突变的生物学机制;MAPK/PI3K 信号通路;BRAF/MEK 抑制剂评估;PI3K/mTOR 抑制剂评估;联合治疗策略;甲状腺癌耐药性
Synonyms
  • Ocut-2C
  • OCUT2C
  • Osaka City University Thyroid-2C

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
GMO status
Non-GMO
GMO status details
No genetic modification; wildtype anaplastic thyroid carcinoma cell line with somatic BRAF V600E and PIK3CA H1047R mutations
Biosafety level
1

03Characteristics

Morphology
上皮样
Cell type
上皮细胞
Doubling time
约24至48小时

04Identifiers

Citation
OCUT-2C(Cytion 产品编号 305544)
NCBI TaxID
9606
Cellosaurus
CVCL_W915

05Expression and susceptibility

Mutational profile
突变:p.Val600Glu,未指定;突变:p.His1047Arg,未指定

06Handling and culture

Culture medium
RPMI 1640,w:2.0 mM 稳定谷氨酰胺,w:2.0 g/L NaHCO3(Cytion 文章编号 820700a)。
Incubation atmosphere

37°C, 5%CO2, 加湿环境。

Supplements
在培养基中添加 10% FBS
Dissociation reagent
Accutase
Subculturing
移除培养基,用不含钙和镁的PBS洗涤,加入Accutase覆盖细胞,在室温下孵育8–10分钟,用培养基重悬细胞,以300×g离心3分钟,弃去上清液,将细胞接种到新鲜培养基中。
Split ratio
1 到 5
Seeding density
1 至 3 × 10⁴ 个细胞/cm²
Fluid renewal
每 2 至 3 天
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
作为冷冻保存培养基,我们使用完全生长培养基+10% DMSO,以获得足够的解冻后存活率。
Storage conditions

如需长期保存,可将样品瓶放入气相液氮中,温度约为 -150 至 -196 ℃。在-80 °C下保存只能作为转入液氮前的短暂过渡。

Shipping conditions

冷冻保存的细胞系用干冰装运,并用经过验证的隔热包装和足够的制冷剂在整个运输过程中保持约 -78 °C 的温度。收到货后,应立即检查容器,并立即将小瓶转移到适当的储藏室。

08Donor

Donor age
81Y
Ethnicity
日语